Please type a plus sign (+) inside this box \rightarrow

PTOSRIBAN (10-96
Approved for use through 1001) MR (406 (65 (4) 03)
Petrot and Torkmark Office: 11.5 (DEPARTMENT OF COMMERCE:

| St | ubstitute for | form 1449 | VPTO | Complete if Known | | |
|----|---------------|-------------|--|------------------------|-------------------|--|
| | STA | ATEME | TION DISCLOSURE NT BY APPLICANT ny sheets as necessary) | Application Number | 09/709,045 | |
| | | (000 00 114 | ny sneets as necessary; | Filing Date | November 10, 2000 | |
| | | | | First Named Inventor | M. Rigdon Lentz | |
| | | | | Group Art Unit | 1647 | |
| | | | | Examiner Name | Lorraine Spector | |
| | 1 | of | 2 | Attorney Docket Number | LEN 102 | |

| | | | U.S. PATENT DOCU | MENTS | | |
|--------------------------------|---|-----------|-------------------|------------|--|--|
| xaminer Cite Initials* No.1 | | | of Cited Document | | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | |
| - | | 5,359,037 | Walfach | 10-25-1994 | | |
| | | 6,232,446 | Wallach | 05-15-2001 | | |
| | | 6,982,089 | Tobinick | 01-03-2006 | | |
| | | 7,236,776 | Hauptmann | 07-03-2007 | | |
| | - | - | | | | |
| | | | | | | |
| | - | | | | | |
| | | | | | | |

| | | | | | OREIGN PATENT DOCUMEN | TS | | |
|-----------------------|--------------|-------------------------|------------------------|--------------------------------------|--|---|---|----|
| Examiner Initials* | Cite No.1 | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM- DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | Te |
| | | Office. ⁸ | Number* | Kind Code ⁵ (If known) | | | | |
| | | JP | 6 296860 (Abstract) | | Asahi Medical Co. Ltd. | 10-25-1994 | | |
| | | PCT | WO 97/014964 | | Heinrich, et al. | 04-24-1997 | | ļ |
| | | | | | | | | |
| | _ | | | <u> </u> | | | | - |
| | | | | | | | | |
| <u> </u> | | + | | | | - | | - |
| | | | | | | | | 1 |

| Examiner's | Date Considered |
|------------|-----------------|
| Cignotuse | |
| Signature | |
| | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete his form should be sent to the Chief Information Officer, Patent and Tindemark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SENT TO: Assistant Commission Fe Patent, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SENT TO: Assistant Commission Fe Patent, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SENT TO: Assistant Commission Fe Patent, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SENT TO: Assistant Commission Feet Patent, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SENT TO: Assistant Commission Feet Patent, Washington, DC 20231, DO NOT SEND FEET SENT TO THE ADDRESS OR THE PATENT TO TH

¹ Unique, calation designation number ² See attached Kinds of U.S. Patent Documents. ¹ Eater Office that issued the document, by the Austrian Standard ST33, ² For Jacophere patent documents, the indication of the year of the region of the Emperor must precede the seath of the patent document. ² Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, ⁴ Applicant to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-96
Approved for use through 10/31/9R, CMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| Under the Paperwo | rk Reduction Act of 1 | 1995, no persons a | are required to respond to a collection of information ur | niess it contains a valid OMB control number | | |
|-------------------------------|-----------------------|--------------------|---|--|-------------------|--|
| Substitute for form 1449A/PTO | | | VPTO | Complete if Known | | |
| | STA | TEMEN | TION DISCLOSURE NT BY APPLICANT ny sheets as necessary) | Application Number | 09/709,045 | |
| | , | | ,,,, | Filing Date | November 10, 2000 | |
| | | | | First Named Inventor | M. Rigdon Lentz | |
| | | | | Group Art Unit | 1647 | |
| | | | | Examiner Name | Lorraine Spector | |
| Sheet | 2 | of | 2 | Attorney Docket Number | LEN 102 | |

OTHER ART. MON DATENT LITERATURE DOCUMENTS

| | | OTHER ART NON PATENT LITERATURE DOCUMENTS | |
|-------------------------|--------------|--|----|
| Examiner's Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the litem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), published | T² |
| | | SUZUKI, "A prospect of anti-cytokine therapy,", Igaku no Ayumi, Japan, Ishiyaku Publishers, Inc., 167(5):432-435 (1993). | |
| | | OLSSON, "Isolation and characterization of a tumor necrosis factor binding protein from urine", Eur. J. Haematol., 42(3):270-275 (1989). | |
| | | PEETRE, "A tumor necrosis factor binding protein is present in human biological fluids", Eur. J. Haematol., 41(3):414-419 (1988). | |
| | | | |
| | | | |
| | | | |
| | | | _ |
| | | · | |
| | | | |
| | | | |
| | L | | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /CMW/

| Examiner's Signature | /Cherie M. Woodward/ | Date Considered 11/08/2011 |
|-------------------------|----------------------|----------------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

** Unique classion designation number** See attached Kinds of U.S. Patent Documents.** Einer Office that issued the document, by the two-letter code (MIPD Standard ST3).** For Asparses patent documents, the incidiation of the pase of the relay on the Emparty must precede the sensit number of the patent document. ** forcit of document by the appropriate symbols as indicated on the document under WIPD Standard ST. 16* possible.** Applicant by place a crieck math there it English language Translation is attack.**

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Parient and Trademark Office, Washington, DC 20231. DO NOT SEXID FEES OR COMPLETED FORMS TO THIS ADDRESS, SENT TO X. Assistant Commission for Patent, Washington, DC 20231.